Loading...

OSRH OSR HOLDINGS INC Company Mergers 8-K Filing

SR H

SRH

OSR HOLDINGS INC

(OSRH)

2026 8-K

Filing Correction

License Agreement Update

Investor Call Disclosure

Nasdaq Compliance Notice

Woori Acquisition Completed

Exclusive License Agreement

License Agreement

Major Acquisition Announcement

Stockholder Meeting Results

Nasdaq Compliance Notice

Financing Agreement Update

Investor Meetings

Debt-Equity Swaps

Financial Update

Management Change

Stock Purchase Agreement

Business Combination

Business Combination

Business Combination

Promissory Note Amendments

Promissory Note Amendment

Investment Agreement

Charter Amendments

Promissory Note Issued

Promissory Note Issued

Nasdaq Compliance

Promissory Note Amendments

Business Combination Extension

Nasdaq Compliance Issue

Business Combination Extension

Promissory Note Issued

Appointment of Director

Resignations and Non-Compli...

Amended Business Combinatio...

Promissory Note and Charter...

Adjournment of Special Meet...

Promissory Note Issued

Promissory Note Issued

Delisting Notice

Promissory Note and Charter...

Merger Agreement

Promissory Note Issued and ...

Resignation of Director

IPO and Private Placement

Appointment of Directors an...

IPO of subsidiary or associ...

External Links:

On January 13, 2025, OSR Holdings, Inc. announced a Binding Term Sheet with BCM Europe AG for an exclusive license of its VXM01 oral cancer immunotherapy, with an initial payment of $30 million and potential milestones of up to $815 million.

AI Assistant

OSR HOLDINGS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.